[ad_1]
Acumen Prescribed drugs, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical firm growing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the remedy of Alzheimer’s illness (AD), at present introduced that it’s going to current new findings on the upcoming 18th Annual Medical Trials on Alzheimer’s Illness (CTAD) convention happening in San Diego. The displays embody Acumen’s recruitment methods for its Part 2 ALTITUDE-AD examine of sabirnetug, in addition to a nonclinical Enhanced Mind Supply (EBD™) examine specializing in fusing transferrin receptor binders to sabirnetug to facilitate its transport by the blood-brain barrier. The convention will probably be held in-person December 1-4, 2025.
Sabirnetug, Acumen’s lead program, is the primary humanized monoclonal antibody to reveal in early symptomatic AD sufferers selective goal engagement of AβOs, a soluble and extremely synaptotoxic type of Aβ that accumulates early in AD and is a persistent set off of synaptic dysfunction and neurodegeneration. Enrollment within the Part 2 examine of sabirnetug, ALTITUDE-AD, was accomplished in March 2025.
Moreover, Acumen’s analysis on EBD was carried out with JCR Prescribed drugs (“JCR”) as a part of its ongoing collaboration introduced in July 2025 . The objective of this collaboration is to develop a product leveraging Acumen’s AβO-selective antibody experience and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating expertise – in an effort to doubtlessly enhance drug supply to the mind and doubtlessly provide sufferers a more practical remedy choice with an improved security profile, to sluggish or forestall neurodegeneration related to AD.
Acumen’s presentation particulars are as follows:
Matter: P019 ALTITUDE-AD: Recruitment methods for a worldwide part 2 trial of sabirnetug in early Alzheimer’s illness
Date/Time: Monday, December 1, 3:00 p.m. – Tuesday, December 2, 5:30 p.m. PST
Format: Poster Presentation
Session: Medical trials: methodology
Presenting Writer: Robyn Moxon, MA, Affiliate Director, Communications, Acumen Prescribed drugs
Matter: P381 Fusing Transferrin Receptor Binders to the AβO-targeting Antibody Sabirnetug Achieves Elevated Mind Penetration in Mice Whereas Preserving Goal Binding
Date/Time: Thursday, December 4, 7:15 a.m. – 5:00 p.m. PST
Format: Poster Presentation
Session: Animal mannequin and Preclinical trials in AD
Presenting Writer: Elizabeth Johnson, Ph.D., Senior Bioanalytical Scientist, Acumen Prescribed drugs
About Sabirnetug (ACU193)
Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) found and developed primarily based on its selectivity for soluble amyloid beta oligomers (AβOs), that are a extremely poisonous and pathogenic type of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been noticed to be potent neurotoxins that bind to neurons, inhibit synaptic perform and induce neurodegeneration. By selectively focusing on poisonous soluble AβOs, sabirnetug goals to handle the speculation that soluble AβOs are an early and chronic underlying reason for the neurodegenerative course of in Alzheimer’s illness (AD). Sabirnetug has been granted Quick Observe designation for the remedy of early AD by the U.S. Meals and Drug Administration and is at the moment being evaluated in a Part 2 examine in sufferers with early AD.
About ALTITUDE-AD (Part 2)
Initiated in 2024, ALTITUDE-AD is a Part 2, multi-center, randomized, double-blind, placebo-controlled medical trial designed to guage the efficacy and security of sabirnetug (ACU193) infusions administered as soon as each 4 weeks in slowing cognitive and practical decline as in comparison with placebo in contributors with early Alzheimer’s illness. The examine has enrolled 542 people with early Alzheimer’s illness (delicate cognitive impairment or delicate dementia on account of AD) at a number of investigative websites situated in the USA, Canada, the European Union and the UK. Extra info might be discovered on www.clinicaltrials.gov, NCT identifier NCT06335173.
About Acumen Prescribed drugs, Inc.
Acumen Prescribed drugs is a clinical-stage biopharmaceutical firm growing a novel therapeutic that targets poisonous soluble amyloid beta oligomers (AβOs) for the remedy of Alzheimer’s illness (AD). Acumen’s scientific founders pioneered analysis on AβOs, which a rising physique of proof signifies are early and chronic triggers of Alzheimer’s illness pathology. Acumen is at the moment centered on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Part 2 medical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s illness sufferers, following optimistic leads to its Part 1 trial INTERCEPT-AD. The corporate is headquartered in Newton, Mass. For extra info, go to www.acumenpharm.com .
In regards to the J-Mind Cargo ® Platform Know-how
JCR Prescribed drugs has developed a proprietary blood-brain barrier (BBB)-penetrating expertise, J-Mind Cargo ® , to deliver biotherapeutics into the central nervous system (CNS). The primary drug developed primarily based on this expertise is IZCARGO ® (INN: pabinafusp alfa) and is authorised in Japan for the remedy of a lysosomal storage dysfunction.
About JCR Prescribed drugs Co., Ltd.
JCR Prescribed drugs Co., Ltd. (TSE 4552) is a worldwide specialty pharmaceutical firm that develops therapies that transcend uncommon illnesses to unravel the world’s most advanced healthcare challenges. We proceed to construct upon our 50-year legacy in Japan whereas increasing our international footprint into the U.S., Europe, and Latin America. We enhance sufferers’ lives by making use of our scientific experience and distinctive applied sciences to analysis, develop, and ship next-generation therapies. Our authorised merchandise in Japan embody therapies for the remedy of development dysfunction, MPS II (Hunter syndrome), Fabry illness, acute graft-versus host illness, and renal anemia. Our investigational merchandise in improvement worldwide are geared toward treating uncommon illnesses together with MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome sort A and B), and extra. Our core values – Placing folks first, Forging our personal path, At all times advancing, and Dedicated to excellence – imply that the work we do advantages all our stakeholders, together with companions, sufferers and workers. We attempt to broaden the chances for sufferers whereas accelerating medical development at a worldwide stage. For extra info, please go to JCR’s international web site: https://jcrpharm.com/ .
Ahead-Trying Statements
This press launch accommodates forward-looking statements throughout the which means of The Personal Securities Litigation Reform Act of 1995. Any assertion describing Acumen’s targets, expectations, monetary or different projections, intentions or beliefs is a forward-looking assertion and must be thought of an at-risk assertion. Phrases corresponding to “believes,” “expects,” “anticipates,” “might,” “ought to,” “would,” “seeks,” “goals,” “plans,” “potential,” “will,” “milestone” and related expressions are meant to establish forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Ahead-looking statements embody statements regarding Acumen’s enterprise, the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), and the potential to develop an EBD candidate to deal with Alzheimer’s Illness using blood-brain-barrier (BBB) expertise. These statements are primarily based upon the present beliefs and expectations of Acumen administration, and are topic to sure elements, dangers and uncertainties, significantly these inherent within the technique of discovering, growing and commercializing secure and efficient human therapeutics. Such dangers could also be amplified by the impacts of geopolitical occasions and macroeconomic circumstances, corresponding to rising inflation, provide disruptions and uncertainty of credit score and monetary markets. These and different dangers regarding Acumen’s applications are described in further element in Acumen’s filings with the Securities and Trade Fee (“SEC”), together with in Acumen’s most up-to-date Annual Report on Kind 10-Okay, and in subsequent filings with the SEC. Copies of those and different paperwork can be found from Acumen. Further info will probably be made accessible in different filings that Acumen makes once in a while with the SEC. These forward-looking statements communicate solely as of the date hereof, and Acumen expressly disclaims any obligation to replace or revise any forward-looking assertion, besides as in any other case required by legislation, whether or not, on account of new info, future occasions or in any other case.
Traders:
Alex Braun
abraun@acumenpharm.com
Media:
Jon Yu
ICR Healthcare
AcumenPR@icrhealthcare.com
[ad_2]
